The value of a second, confirming assay is further supported by an analysis of ENIGMA data and two functional assays (KAP1 phosphorylation and CHK2 phosphorylation) carried out by Stolarova et al. [22], which shows that CHK2 variants confirmed to be damaging in more assays are associated with increasing risk for breast cancer. This evidence concerns the gene CHEK2 and breast carcinoma.